文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

嗜铬细胞瘤与副神经节瘤放射性药物诊疗一体化近期进展

Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma.
PubMed 文献 · Semin Nucl Med · 2023-01-13

本文综述嗜铬细胞瘤与副神经节瘤(PGL)放射性药物诊疗一体化的近期进展,涵盖123/131I-MIBG、肽受体放射性核素治疗及α发射体等。高比活度131I-MIBG于2018年获美国食品药品监督管理局批准用于转移性PGL的全身治疗;68Ga-生长抑素类似物PET在诊断PGL方面表现优于MIBG显像。

要点

  • 123/131I-MIBG靶向去甲肾上腺素转运体系统,疾病控制良好且毒性有限。
  • 高比活度131I-MIBG于2018年获美国食品药品监督管理局批准用于转移性PGL全身治疗。
  • 68Ga-生长抑素类似物PET诊断PGL优于MIBG显像,头颈部PGL或SDHx突变者尤甚。

核心结论

  • 放射性药物在PGL管理中发挥不可或缺的作用,诊疗一体化已被视为诊断、分期、监测和治疗规划的可能手段。
  • 许多α发射体研究仍处于临床前阶段,需要更多研究。

研究设计与样本

  • 本文为综述,总结PGL放射性药物诊疗一体化的发展与近期进展。

主要发现

  • 123/131I-MIBG靶向去甲肾上腺素转运体系统,因疾病控制良好且毒性有限,仍是PGL患者的优良方案。
  • 68Ga-生长抑素类似物PET诊断PGL的表现显著优于MIBG显像,尤其在头颈部PGL或SDHx突变患者中。
  • 90Y/177Lu-DOTA-生长抑素类似物疗效高度成功且安全性良好,客观缓解、疾病稳定、症状与激素控制及生活质量保持方面的证据不断增多。
  • 211At-MABG和225Ac-DOTATATE等α发射体近年来得到深入研究,但许多研究仍处于临床前阶段。

关键数值与推荐

  • 高比活度131I-MIBG于2018年获美国食品药品监督管理局批准,作为转移性PGL的全身治疗方法。

临床怎么用

  • 综述指出放射性药物在PGL管理中发挥不可或缺的作用,诊疗一体化被视为诊断、分期、监测和治疗规划的可能手段。
  • 综述指出高比活度131I-MIBG因疾病控制良好且毒性有限,仍是PGL患者的优良方案。

局限性

  • 许多α发射体研究仍处于临床前阶段,需要更多研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As a rare kind of non-epithelial neuroendocrine neoplasms, paragangliomas (PGLs) exhibit various clinical characteristics with excessive catecholamine secretion and have been a research focus in recent years. Although several modalities are available nowadays, radiopharmaceuticals play an integral role in the management of PGLs. Theranostics utilises radiopharmaceuticals for diagnostic and therapeutic intentions by aiming at a specific target in tumour and has been considered a possible means in diagnosis, staging, monitoring and treatment planning. Numerous radiopharmaceuticals have been developed over the past decades. 123/131-Metaiodobenzylguanidine (123/131I-MIBG), the theranostics pair target on norepinephrine transporter system, has remained a fantastic protocol for patients with PGLs because of disease control with limited toxicity. The high-specific-activity 131I-MIBG was authorised by the Food and Drug Administration as a systemic treatment method for metastatic PGLs in 2018. Afterward, peptide receptor radionuclide therapy, which uses radiolabelled somatostatin (SST) analogues, has been exploited as a superior substitute. 68Ga-somatostatin analogue (SSA) PET showed significant performance in diagnosing PGLs than MIBG scintigraphy, especially in patients with head and neck PGLs or SDHx mutation. 90Y/177Lu-DOTA-SSA is highly successful and has preserved favourable safety with mounting evidence regarding objective response, disease stabilisation, symptomatic and hormonal management and quality of life preservation. Besides the ordinary beta emitters, alpha-emitters such as 211At-MABG and 225Ac-DOTATATE have been investigated intensively in recent years. However, many studies are still in the pre-clinical stage, and more research is necessary. This review summarises the developments and recent advances in radiopharmaceutical theranostics of PGLs.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhang X, Wakabayashi H, Hiromasa T, et al. Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma. Semin Nucl Med. 2023. PMID: 36641337. doi:10.1053/j.semnuclmed.2022.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。